Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2016-06-03

Clinical Trial Update: Monoclonal Antibody CT-011 in Combination With Rituximab in Patients With Relapsed Follicular Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating CT-011 in combination with rituximab for relapsed follicular lymphoma has completed, with results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • CT-011
  • Rituximab (rituximab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2016-06-03